Neoadjuvant Concurrent Radiotherapy and Chemotherapy in Early Breast Cancer Patients: Long-Term Results of a Prospective Phase II Trial

Autor:	Fatima Laki, Youlia M. Kirova, Alain Fourquet, Jean-Yves Pierga, Anne Vincent-Salomon, Diane Jornet, Pierre Loap
Přispěvatelé:	Institut Curie [Paris], Université de Versailles Saint-Quentin-en-Yvelines - UFR Sciences de la santé Simone Veil (UVSQ Santé), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)
Jazyk:	angličtina
Rok vydání:	2021
Předmět:	prospective phase II Cancer Research medicine.medical_specialty medicine.medical_treatment Breast surgery Urology Phases of clinical research [SDV.CAN]Life Sciences [q-bio]/Cancer Vinorelbine Article 03 medical and health sciences 0302 clinical medicine Breast cancer breast cancer medicine 030212 general & internal medicine Telangiectasia RC254-282 Chemotherapy long term results business.industry Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease 3. Good health Radiation therapy Oncology 030220 oncology & carcinogenesis medicine.symptom business Mastectomy neoadjuvant concurrent radiotherapy and chemotherapy medicine.drug
Zdroj:	Cancers Volume 13 Issue 20 Cancers, MDPI, 2021, 13 (20), ⟨10.3390/cancers13205107⟩ Cancers, Vol 13, Iss 5107, p 5107 (2021)
ISSN:	2072-6694
DOI:	10.3390/cancers13205107
Popis:	Simple Summary The originality of this prospective study is to use radiation therapy in association with chemotherapy before surgery and permit patients to preserve their breasts or to undergo immediate reconstruction. This neoadjuvant strategy can therefore allow one-stage breast reconstructive surgery, the so-called “reverse technique”. Abstract Background: Neoadjuvant concurrent radiochemotherapy makes it possible to increase the breast conservation rate. This study reports the long term outcome of this treatment. Methods: From 2001 to 2003, 59 women with T2–3 N0–2 M0 invasive breast cancer (BC) not amenable to upfront breast conserving treatment (BCS) were included in this prospective, non-randomized phase II study. Chemotherapy (CT) consisted of four cycles of continuous 5-FU infusion and Vinorelbine. Starting concurrently with the second CT cycle, normofractionated RT was delivered to the breast and LN. Breast surgery was then performed. Results: Median follow-up (FU) was 13 years [3–18]. BCS was performed in 41 (69%) patients and mastectomy in 18 patients, with pathological complete response rate of 27%. Overall and distant-disease free survivals rates at 13 years were 70.9% [95% CI 59.6–84.2] and 71.5% [95% CI 60.5–84.5] respectively. Loco regional and local controls rates were 83.4% [95% CI 73.2–95.0] and 92.1% [95% CI 83.7–100], respectively. Late toxicity (CTCAE-V3) was assessed in 51 patients (86%) with a median follow-up of 13 years. Fifteen presented grade 2 fibrosis (29.4%), 8 (15.7%) had telangiectasia, and 1 had radiodermatitis. Conclusions: This combined treatment provided high long-term local control rates with limited side-effects.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a903d574fad873383956a9f12fbd84e9 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.